Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients

Table 1

The clinical characteristics of COVID-19 patients treated with TCZ.

Case no.	Age	Clinical classification	Comorbidity	Time from onset to before TCZ therapy (days)	TCZ therapy
					Day 0	Day 1	Day 2	Day 3	Days 4–7
1	83	Critically ill	Hypertension	15	TCZ 480 mg; MP 40 mg	MP 40 mg
2	54	Critically ill	Diabetes	17	TCZ 400 mg	TCZ 400 mg
3	62	Moderately ill	Diabetes CHD	37	TCZ 400 mg
4	83	Seriously ill	Hypertension diabetes	22	TCZ 200 mg
5	71	Seriously ill	None	22	TCZ 400 mg
6	66	Seriously ill	None	9	TCZ 280 mg
7	62	Seriously ill	Stroke history	20	TCZ 400 mg; MP 40 mg	MP 40 mg
8	79	Seriously ill	Hypertension COPD	14	TCZ 200 mg
9	63	Seriously ill	CHD	41	TCZ 200 mg
10	68	Critically ill	COPD	40	TCZ 400 mg	TCZ 400 mg
11	60	Seriously ill	Hypertension diabetes	12	TCZ 400 mg
12	72	Critically ill	Hypertension CHD	10	TCZ 400 mg
13	69	Seriously ill	Hypertension	32	TCZ 400 mg

M: male, F: female. MP: methylprednisolone. CHD: coronary heart disease. COPD: chronic obstructive pulmonary diseases.